重组人白细胞介素11(迈格尔)治疗慢性再生障碍性贫血的血小板减少症10例临床研究报告

Clinical Report on Treatment of Thrombocytopenia with rhIL-11(Mega) in 10 Chronic Aplastic Anemia Patients

研究重组人白细胞介素11(迈格尔)对慢性再生障碍性贫血的血小板减少症的治疗作用。选择经过传统药物治疗而血小板仍处于较低水平的10例慢性再生障碍性贫血患者,在传统治疗的基础上每天皮下注射迈格尔0.75 mg,治疗1-2疗程,每个疗程15天。结果表明:治疗后所有患者血小板数明显增加,与此同时病人的临床出血症状也随之改善,取得了较满意的效果。结论:迈格尔对慢性障碍性贫血的血小板减少症有较好的治疗效果。

In order to evaluated the curative effect of rhIL-11 (Mega) on thrombocytopenia in chronic aplastic anemia (CAA) patients,ten CAA cases with thrombocytopenia after administration of conventional drugs were selected and subutaneously injected 0.75 mg Mega per day in 1-2 courses of treatment on the basis of conventional therapy.Results showed that platelet counts were obviously increased and the bleeding symptoms were alleviated in all CAA patients after application of Mega for trentment.In conclusion,the rhIL-11 (Mega) could be used as an effective drug for treatment of thrombocytopenia in CAA patients.